Overview of the Market:
Asia-Pacific Hemophilia Management Market was worth $1020 million in 2018 and estimated to be growing at a CAGR of 1.78%, to reach $1110 million by 2023. Hemophilia is a genetic disorder which impairs body`s ability to control blood clotting. Hemophilia usually occurs in males it is estimated that about 1 in 5000 males born each year contains some form of hemophilia. Hemophilia is characterized into three levels depending upon on its severity as severe, moderate and mild. Around 80% of the patients suffering from hemophilia are considered to be severe. The worldwide incidence of hemophilia is estimated at more than 400,000 people. Asia-Pacific Hemophilia Management market is driven by factors such as growing prevalence of the disease and increasing usage of recombinant product. Advancements in technology and rising investments into Research and developments are also fuelling the market growth. However lack of awareness about the disease and limited access to the medication are the key factors hindering the market growth. Advancements in gene therapy which help in the treatment of hemophilia also provide immense growth opportunities. Asia-Pacific Hemophilia management market is segmented on the basis of type of hemophilia and type of drug. By type of hemophilia it is further sub segmented into Hemophilia A and Hemophilia B. On the basis of drug type it is further sub segmented into Octocogalfa, Nonacogalfa, Desmopressin and other drugs. Hemophilia A is the largest segment accounting for approximately XX% due to elevated incidence of the condition.
Geographical Analysis:
Based on geography Asia-Pacific hemophilia management market is analyzed under various regions namely China, India, Japan, South Korea and Australia. Asia-Pacific region is estimated to be the fastest growing region owing to its high population base and increasing healthcare expenditure. Within Asia-Pacific, Japan is a major market for hemophilia management due to high government support and wide spread awareness about the treatment options for hemophilia. India is estimated to grow at highest CAGR due to increasing incidence of the hemophilia.
Key Players in this Market:
Some of the major companies discussed in the report are Biogen, Baxter International Inc., Pfizer Inc., Bayer Pharma AG, Novo Nordisk A/S, Grifols International SA, CSL Behring, Octapharma and Swedish Orphan Biovitrum AB
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 BY Type
5.1.1 Hemophilia A
5.1.2 Hemophilia B
5.2 By Drug
5.2.1 Octocogalfa
5.2.2 Nonacogalfa
5.2.3 Desmopressin
5.2.4 Other drugs
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Biogen
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Pfizer Inc.
8.3 Baxter International Inc.
8.4 Bayer Pharma AG
8.5 Novo Nordisk A/S
8.6 Grifols International SA
8.7 CSL Behring
8.8 Octapharma
8.9 Swedish Orphan Biovitrum AB
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
